Iovance Biotherapeutics Stock Fundamentals
| IOVA Stock | USD 10.59 1.69 13.76% |
Iovance Biotherapeutics fundamentals help investors to digest information that contributes to Iovance Biotherapeutics' financial success or failures. It also enables traders to predict the movement of Iovance Stock. The fundamental analysis module provides a way to measure Iovance Biotherapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Iovance Biotherapeutics stock.
At present, Iovance Biotherapeutics' Depreciation And Amortization is projected to increase significantly based on the last few years of reporting. The current year's Interest Expense is expected to grow to about 3.6 M, whereas Operating Income is projected to grow to (437.5 M). Iovance | Select Account or Indicator |
Iovance Biotherapeutics Company Operating Margin Analysis
Iovance Biotherapeutics' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Iovance Biotherapeutics Operating Margin | (1.52) % |
Most of Iovance Biotherapeutics' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Iovance Biotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Iovance Biotherapeutics has an Operating Margin of -1.5211%. This is 95.66% lower than that of the Biotechnology sector and 98.64% lower than that of the Health Care industry. The operating margin for all United States stocks is 72.39% lower than that of the firm.
Iovance Biotherapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Iovance Biotherapeutics's current stock value. Our valuation model uses many indicators to compare Iovance Biotherapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Iovance Biotherapeutics competition to find correlations between indicators driving Iovance Biotherapeutics's intrinsic value. More Info.Iovance Biotherapeutics is rated fourth overall in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Iovance Biotherapeutics' Return On Equity is projected to increase based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Iovance Biotherapeutics' earnings, one of the primary drivers of an investment's value.Iovance Biotherapeutics' Earnings Breakdown by Geography
Iovance Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Iovance Biotherapeutics' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Iovance Biotherapeutics could also be used in its relative valuation, which is a method of valuing Iovance Biotherapeutics by comparing valuation metrics of similar companies.Iovance Biotherapeutics is currently under evaluation in operating margin category among its peers.
Iovance Biotherapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Iovance Biotherapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Iovance Biotherapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Iovance Fundamentals
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.33 | ||||
| Operating Margin | (1.52) % | ||||
| Current Valuation | 2.91 B | ||||
| Shares Outstanding | 304.78 M | ||||
| Shares Owned By Insiders | 0.52 % | ||||
| Shares Owned By Institutions | 87.14 % | ||||
| Number Of Shares Shorted | 60.34 M | ||||
| Price To Earning | (3.51) X | ||||
| Price To Book | 4.17 X | ||||
| Price To Sales | 35.51 X | ||||
| Revenue | 1.19 M | ||||
| EBITDA | (427.43 M) | ||||
| Net Income | (444.04 M) | ||||
| Cash And Equivalents | 424.46 M | ||||
| Cash Per Share | 2.69 X | ||||
| Total Debt | 75.86 M | ||||
| Debt To Equity | 0.17 % | ||||
| Current Ratio | 6.72 X | ||||
| Book Value Per Share | 2.28 X | ||||
| Cash Flow From Operations | (361.82 M) | ||||
| Short Ratio | 14.23 X | ||||
| Earnings Per Share | (1.48) X | ||||
| Target Price | 23.92 | ||||
| Number Of Employees | 557 | ||||
| Beta | 0.59 | ||||
| Market Capitalization | 3.23 B | ||||
| Total Asset | 780.35 M | ||||
| Retained Earnings | (2.01 B) | ||||
| Working Capital | 197.54 M | ||||
| Current Asset | 290.82 M | ||||
| Current Liabilities | 10.12 M | ||||
| Net Asset | 780.35 M |
About Iovance Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Iovance Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Iovance Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Iovance Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 0.90 | 0.86 | |
| Total Revenue | 1.2 M | 1.2 M | |
| Cost Of Revenue | 33.1 M | 34.8 M | |
| Stock Based Compensation To Revenue | 47.40 | 42.14 | |
| Sales General And Administrative To Revenue | 20.97 | 18.64 | |
| Research And Ddevelopement To Revenue | 260.45 | 231.50 | |
| Capex To Revenue | 16.87 | 15.00 | |
| Ebit Per Revenue | (348.61) | (366.05) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Iovance Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Iovance Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Iovance Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Iovance Biotherapeutics Stock:Check out Iovance Biotherapeutics Piotroski F Score and Iovance Biotherapeutics Altman Z Score analysis. For information on how to trade Iovance Stock refer to our How to Trade Iovance Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iovance Biotherapeutics. If investors know Iovance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iovance Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.48) | Revenue Per Share 0.327 | Quarterly Revenue Growth 123.851 | Return On Assets (0.33) | Return On Equity (0.65) |
The market value of Iovance Biotherapeutics is measured differently than its book value, which is the value of Iovance that is recorded on the company's balance sheet. Investors also form their own opinion of Iovance Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iovance Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iovance Biotherapeutics' market value can be influenced by many factors that don't directly affect Iovance Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iovance Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iovance Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iovance Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.